Christy Nichole Jackson, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-1661 |
Mrs. Relisa Wilson, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-4141 |
Regina Rae Paden, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-539-9271 Fax: 210-916-5102 |
Kathleen E. Hewitt, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Brooke Army Medical Center, Fort Sam Houston, TX 78234 Phone: 210-916-1598 |
News Archive
According to a review of dozens of clinical trials, cutting down on calories and exercising are the best ways of shaking off that extra weight over the long-term.
Since the isolation of morphine from opium in the 19th century, scientists have hoped to find a potent opioid analgesic that isn't addictive and doesn't cause respiratory arrest with increased doses.
"We are extremely pleased with the outcome of this event," commented Paul Dodds, deVere and Partner's Managing Partner in Switzerland. "We raised a significant amount for charities that will help improve the lives of children in Switzerland and in the UK. Our partnership with the Geneva appeal for Children in Need was a success and we look forward to working on future events together."
Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE) , announced today that it has received approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis.
MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.
› Verified 9 days ago